Sensory Cloud develops aerosol therapies, with their flagship product Fend using alkaline hypersaline aerosols to improve immunity and treat chronic respiratory conditions.
About the company
Sensory Cloud is a health technology company dedicated to pioneering the development of aerosol therapies designed to enhance human immunity and combat the adverse effects of dry and polluted air on respiratory health. Their flagship product, Fend, leverages alkaline hypersaline solution (HDS) aerosols to offer a novel approach for the treatment of refractory chronic cough (rCC) and potentially other respiratory conditions.
Why We Invested
Methods for managing respiratory health often involve treatments that can be invasive or systemic, with potential side effects. FEND introduces a pioneering solution that utilizes a gentle, ultra-fine mist of hydrating salts to strengthen the body’s natural air filtration capabilities. This innovation comes from decades of research by founder David Edwards and teams at leading institutions like MIT and Harvard, proving the effectiveness of targeted upper airway hydration.
Many respiratory health approaches do not leverage the preventive potential of enhancing the body's natural defenses. FEND’s method of delivering precise blends of calcium and magnesium salts directly to the upper airways offers a non-invasive, efficient, and long-lasting way to improve airway cleanliness and overall respiratory health.
By investing in FEND, we are endorsing a shift toward more natural and less intrusive health interventions. This investment is aligned with our commitment to supporting technologies that not only enhance health and well-being but do so through innovative, evidence-based strategies that prioritize safety and efficacy. FEND is at the forefront of redefining respiratory health care, making it a key addition to our portfolio of health technology advancements.